GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Cyclically Adjusted Price-to-FCF

Emmaus Life Sciences (Emmaus Life Sciences) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emmaus Life Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Cyclically Adjusted Price-to-FCF Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



Emmaus Life Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Emmaus Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Emmaus Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Emmaus Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -11.733 98.326 -15.496
201403 -9.904 99.695 -12.901
201406 -8.226 100.560 -10.623
201409 -8.271 100.428 -10.695
201412 -9.341 99.070 -12.244
201503 -6.471 99.621 -8.435
201506 -4.341 100.684 -5.599
201509 -5.224 100.392 -6.757
201512 -7.153 99.792 -9.308
201603 -8.512 100.470 -11.002
201606 -8.416 101.688 -10.748
201609 -2.972 101.861 -3.789
201612 -2.200 101.863 -2.805
201703 -2.329 102.862 -2.940
201706 -2.584 103.349 -3.247
201709 -2.985 104.136 -3.722
201712 -3.418 104.011 -4.267
201803 -3.201 105.290 -3.948
201806 -2.815 106.317 -3.438
201809 -1.519 106.507 -1.852
201812 -1.386 105.998 -1.698
201903 -1.499 107.251 -1.815
201906 -1.232 108.070 -1.480
201909 0.000 108.329 0.000
201912 0.012 108.420 0.014
202003 0.037 108.902 0.044
202006 -0.072 108.767 -0.086
202009 -0.054 109.815 -0.064
202012 0.039 109.897 0.046
202103 -0.082 111.754 -0.095
202106 0.005 114.631 0.006
202109 0.033 115.734 0.037
202112 0.018 117.630 0.020
202203 -0.096 121.301 -0.103
202206 -0.022 125.017 -0.023
202209 -0.019 125.227 -0.020
202212 0.034 125.222 0.035
202303 -0.026 127.348 -0.027
202306 -0.025 128.729 -0.025
202309 0.000 129.860 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emmaus Life Sciences  (OTCPK:EMMA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Emmaus Life Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501